|
1
|
Ondrusova M, Ondrus D, Karabinos J, Muzik
J, Kliment J and Gulis G: Trends in prostate cancer incidence and
mortality before and after the introduction of PSA testing in the
Slovak and Czech Republics. Tumori. 97:149–155. 2011.PubMed/NCBI
|
|
2
|
Glass AS, Cary KC and Cooperberg MR:
Risk-based prostate cancer screening: Who and how? Curr Urol Rep.
14:192–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DrudgeCoates L and Turner B: Prostate
cancer overview. Part 1: Non-metastatic disease. Br J Nurs. 21
(Suppl 9):S23–S28. 2012. View Article : Google Scholar
|
|
4
|
Sivoňová MK, Dobrota D, Dušenka R,
Waczulíková I, Slezák P, Matáková T, Mahmoodová S, Mištuna D and
Kliment J: Effect of CYP17 and PSA gene polymorphisms on prostate
cancer risk and circulating PSA levels in the Slovak population.
Mol Biol Rep. 39:7871–7880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sivonova MK, Dobrota D, Matakova T,
Dusenka R, Grobarcikova S, Habala V, Salagovic J, Tajtakova M,
Pidanicova A, Valansky L, et al: Microsomal epoxide hydrolase
polymorphisms, cigarette smoking and prostate cancer risk in the
Slovak population. Neoplasma. 59:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pietsch EC, Humbey O and Murphy ME:
Polymorphisms in the p53 pathway. Oncogene. 25:1602–1611. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y
and Furihata M: Overexpression of p53 protein in human tumors. Med
Mol Morphol. 45:115–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mirzayans R, Andrais B, Scott A and Murray
D: New insights into p53 signaling and cancer cell response to DNA
damage: Implications for cancer therapy. J Biomed Biotechnol.
2012:1703252012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
ElDeiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaul R, Mukherjee S, Ahmed F, Bhat MK,
Chhipa R, Galande S and Chattopadhyay S: Direct interaction with
and activation of p53 by SMAR1 retards cell-cycle progression at
G2/M phase and delays tumor growth in mice. Int J Cancer.
103:606–615. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suzuki H, Ito R, Ikeda K and Tamura TA:
TATA-binding protein (TBP)-like protein is required for
p53-dependent transcriptional activation of upstream promoter of
p21Waf1/Cip1 gene. J Biol Chem. 287:19792–19803. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gartel AL and Tyner AL: The role of the
cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer
Ther. 1:639–649. 2002.PubMed/NCBI
|
|
13
|
Brosh R and Rotter V: When mutants gain
new powers: News from the mutant p53 field. Nat Rev Cancer.
9:701–713. 2009.PubMed/NCBI
|
|
14
|
Matlashewski GJ, Tuck S, Pim D, Lamb P,
Schneider J and Crawford LV: Primary structure polymorphism at
amino acid residue 72 of human p53. Mol Cell Biol. 7:961–963.
1987.PubMed/NCBI
|
|
15
|
Thomas M, Kalita A, Labrecque S, Pim D,
Banks L and Matlashewski G: Two polymorphic variants of wild-type
p53 differ biochemically and biologically. Mol Cell Biol.
19:1092–1100. 1999.PubMed/NCBI
|
|
16
|
Robles AI, Linke SP and Harris CC: The p53
network in lung carcinogenesis. Oncogene. 21:6898–6907. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siddique M and Sabapathy K:
Trp53-dependent DNA-repair is affected by the codon 72
polymorphism. Oncogene. 25:3489–3500. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang JN, Yi SH, Zhang XH, Liu XY, Mao Q,
Li SQ, Xiong WH, Qiu YM, Chen T and Ge JW: Association of p53
Arg72Pro and MDM2 SNP309 polymorphisms with glioma. Genet Mol Res.
11:3618–3628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sucheston L, Witonsky DB, Hastings D,
Yildiz O, Clark VJ, Di Rienzo A and Onel K: Natural selection and
functional genetic variation in the p53 pathway. Hum Mol Genet.
20:1502–1508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Quiñones LA, Irarrázabal CE, Rojas CR,
Orellana CE, Acevedo C, Huidobro C, Varela NE and Cáceres DD: Joint
effect among p53, CYP1A1, GSTM1 polymorphism combinations and
smoking on prostate cancer risk: An exploratory
genotype-environment interaction study. Asian J Androl. 8:349–355.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki K, Matsui H, Ohtake N, Nakata S,
Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K, et al: A p53
codon 72 polymorphism associated with prostate cancer development
and progression in Japanese. J Biomed Sci. 10:430–435. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJ
and Chen WC: p53 gene codon 72 polymorphism but not tumor necrosis
factor-alpha gene is associated with prostate cancer. Urol Int.
73:41–46. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mittal RD, George GP, Mishra J, Mittal T
and Kapoor R: Role of functional polymorphisms of P53 and P73 genes
with the risk of prostate cancer in a case-control study from
Northern India. Arch Med Res. 42:122–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu Y, Liu Y, Zeng J, He Y, Peng Q, Deng Y,
Wang J, Xie L, Li T, Qin X, et al: Association of p53 codon 72
polymorphism with prostate cancer: An update meta-analysis. Tumour
Biol. 35:3997–4005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
RicksSanti L, Mason T, Apprey V, Ahaghotu
C, McLauchlin A, Josey D, Bonney G and Dunston GM: p53 Pro72Arg
polymorphism and prostate cancer in men of African descent.
Prostate. 70:1739–1745. 2010.PubMed/NCBI
|
|
27
|
Leiros GJ, Galliano SR, Sember ME, Kahn T,
Schwarz E and Eiguchi K: Detection of human papillomavirus DNA and
p53 codon 72 polymorphism in prostate carcinomas of patients from
Argentina. BMC Urol. 5:152005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salehi Z and Hadavi M: Analysis of the
codon 72 polymorphism of TP53 and human papillomavirus infection in
Iranian patients with prostate cancer. J Med Virol. 84:1423–1427.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Zhuo WL, Zheng Y and Zhang YS:
Polymorphisms of TP53 codon 72 with prostate carcinoma risk: A
meta-analysis. Med Oncol. 27:540–546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Y, Wang J, He Q and Zhang JQ:
Association of p53 codon 72 polymorphism with prostate cancer: A
meta-analysis. Mol Biol Rep. 38:1603–1607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma H, Zhou Z, Wei S and Wei Q: Association
between p21 Ser31Arg polymorphism and cancer risk: A meta-analysis.
Chin J Cancer. 30:254–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gravina S, Lescai F, Hurteau G, Brock GJ,
Saramaki A, Salvioli S, Franceschi C and Roninson IB:
Identification of single nucleotide polymorphisms in the p21
(CDKN1A) gene and correlations with longevity in the Italian
population. Aging (Albany NY). 1:470–480. 2009.PubMed/NCBI
|
|
33
|
Liu F, Li B, Wei Y, Chen X, Ma Y, Yan L
and Wen T: p21 codon 31 polymorphism associated with cancer among
white people: Evidence from a meta-analysis involving 78,074
subjects. Mutagenesis. 26:513–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li G, Liu Z, Sturgis EM, Shi Q,
Chamberlain RM, Spitz MR and Wei Q: Genetic polymorphisms of p21
are associated with risk of squamous cell carcinoma of the head and
neck. Carcinogenesis. 26:1596–1602. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY,
Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, et al: p53 Codon 72 and
p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol
Biomarkers Prev. 13:2217–2224. 2004.PubMed/NCBI
|
|
36
|
Taghavi N, Biramijamal F, Abbaszadegan MR,
Khademi H, Sotoudeh M and Khoshbakht S: P21(waf1/cip1) gene
polymorphisms and possible interaction with cigarette smoking in
esophageal squamous cell carcinoma in northeastern Iran: A
preliminary study. Arch Iran Med. 13:235–242. 2010.PubMed/NCBI
|
|
37
|
Wigginton JE, Cutler DJ and Abecasis GR: A
note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet.
76:887–893. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Henner WD, Evans AJ, Hough KM, Harris EL,
Lowe BA and Beer TM: Association of codon 72 polymorphism of p53
with lower prostate cancer risk. Prostate. 49:263–266. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shen H, Zheng Y, Sturgis EM, Spitz MR and
Wei Q: P53 codon 72 polymorphism and risk of squamous cell
carcinoma of the head and neck: A case-control study. Cancer Lett.
183:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tada M, Furuuchi K, Kaneda M, Matsumoto J,
Takahashi M, Hirai A, Mitsumoto Y, Iggo RD and Moriuchi T:
Inactivate the remaining p53 allele or the alternate p73?
Preferential selection of the Arg72 polymorphism in cancers with
recessive p53 mutants but not transdominant mutants.
Carcinogenesis. 22:515–517. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Waga S, Hannon GJ, Beach D and Stillman B:
The p21 inhibitor of cyclin-dependent kinases controls DNA
replication by interaction with PCNA. Nature. 369:574–578. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moffatt KA, Johannes WU, Hedlund TE and
Miller GJ: Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin
D(3) are mediated by increased levels of p21 in the prostatic
carcinoma cell line ALVA-31. Cancer Res. 61:7122–7129.
2001.PubMed/NCBI
|
|
44
|
Facher EA, Becich MJ, Deka A and Law JC:
Association between human cancer and two polymorphisms occurring
together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor
gene. Cancer. 79:2424–2429. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W,
Porter AT and Honn KV: Somatic mutations of the WAF1/CIP1 gene in
primary prostate cancer. Oncogene. 11:1395–1398. 1995.PubMed/NCBI
|
|
46
|
Chedid M, Michieli P, Lengel C, Huppi K
and Givol D: A single nucleotide substitution at codon 31 (Ser/Arg)
defines a polymorphism in a highly conserved region of the
p53-inducible gene WAF1/CIP1. Oncogene. 9:3021–3024.
1994.PubMed/NCBI
|
|
47
|
Sivoňová MK, Vilčková M, Jurečeková J,
Hatok J, Dobrota D, Dušenka R and Kliment J: The role of p21 3′UTR
gene polymorphism in the risk of prostate cancer: A pilot study.
Mol Med Rep. 7:986–990. 2013.PubMed/NCBI
|
|
48
|
Kibel AS, Suarez BK, Belani J, Oh J,
Webster R, BrophyEbbers M, Guo C, Catalona WJ, Picus J and
Goodfellow PJ: CDKN1A and CDKN1B polymorphisms and risk of advanced
prostate carcinoma. Cancer Res. 63:2033–2036. 2003.PubMed/NCBI
|
|
49
|
Huang SP, Huang CY, Wang JS, Liu CC, Pu
YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, et al: Prognostic
significance of p53 and X-ray repair cross-complementing group 1
polymorphisms on prostate-specific antigen recurrence in prostate
cancer post radical prostatectomy. Clin Cancer Res. 13:6632–6638.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sun T, Lee GS, Oh WK, Pomerantz M, Yang M,
Xie W, Freedman ML and Kantoff PW: Single-nucleotide polymorphisms
in p53 pathway and aggressiveness of prostate cancer in a Caucasian
population. Clin Cancer Res. 16:5244–5251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kometani T, Yoshino I, Miura N, Okazaki H,
Ohba T, Takenaka T, Shoji F, Yano T and Maehara Y: Benzo[a]pyrene
promotes proliferation of human lung cancer cells by accelerating
the epidermal growth factor receptor signaling pathway. Cancer
Lett. 278:27–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
